Breakthrough trial targets deadly pancreatic cancer with new Antibody-Chemo combo
NCT ID NCT07383922
Summary
This study is testing whether adding a new antibody drug called FG-M108 to standard chemotherapy helps people with advanced pancreatic cancer live longer. It will involve 524 adults whose cancer has a specific protein marker called CLDN18.2 and who haven't had prior treatment for advanced disease. Participants will receive either the new drug combination or standard chemotherapy with a placebo, and researchers will track survival, side effects, and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.